SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Kintara Therapeutics, Inc. – ‘S-1/A’ on 7/11/19 – ‘EX-101.CAL’

On:  Thursday, 7/11/19, at 4:17pm ET   ·   Accession #:  1213900-19-12524   ·   File #:  333-232332

Previous ‘S-1’:  ‘S-1’ on 6/25/19   ·   Next:  ‘S-1’ on 8/1/19   ·   Latest:  ‘S-1/A’ on 10/27/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/11/19  DelMar Pharmaceuticals, Inc.      S-1/A                 71:7.9M                                   Edgar Agents LLC/FA

Pre-Effective Amendment to Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1/A       Amendment No. 1 to Form S-1                         HTML   1.11M 
 2: EX-23.1     Consent of Ernst & Young, LLP                       HTML     19K 
 9: R1          Document and Entity Information                     HTML     34K 
10: R2          Consolidated Condensed Interim Balance Sheets       HTML     90K 
11: R3          Consolidated Condensed Interim Balance Sheets       HTML     41K 
                (Parenthetical)                                                  
12: R4          Consolidated Condensed Interim Statements of Loss   HTML     63K 
                and Comprehensive Loss                                           
13: R5          Consolidated Statements of Changes in               HTML    112K 
                Stockholders' Equity                                             
14: R6          Consolidated Condensed Interim Statements of Cash   HTML     84K 
                Flows                                                            
15: R7          Going Concern, Nature of Operations, and Corporate  HTML     40K 
                History                                                          
16: R8          Significant Accounting Policies                     HTML     81K 
17: R9          Valent Technologies, LLC                            HTML     28K 
18: R10         Derivative Liability                                HTML     61K 
19: R11         Stockholders' Equity                                HTML    227K 
20: R12         Financial Instruments                               HTML     36K 
21: R13         Related Party Transactions                          HTML     22K 
22: R14         Current and Deferred Income Taxes                   HTML     37K 
23: R15         Commitments and Contingencies                       HTML     25K 
24: R16         Supplementary Statement of Cash Flows Information   HTML     31K 
25: R17         Financial Risk Management                           HTML     34K 
26: R18         Subsequent Events                                   HTML     32K 
27: R19         Significant Accounting Policies (Policies)          HTML    129K 
28: R20         Significant Accounting Policies (Tables)            HTML     25K 
29: R21         Derivative Liability (Tables)                       HTML     57K 
30: R22         Stockholders' Equity (Tables)                       HTML    202K 
31: R23         Financial Instruments (Tables)                      HTML     28K 
32: R24         Current and Deferred Income Taxes (Tables)          HTML     47K 
33: R25         Supplementary Statement of Cash Flows Information   HTML     30K 
                (Tables)                                                         
34: R26         Financial Risk Management (Tables)                  HTML     33K 
35: R27         Going Concern, Nature of Operations, and Corporate  HTML     37K 
                History (Details)                                                
36: R28         Significant Accounting Policies (Details)           HTML     30K 
37: R29         Significant Accounting Policies (Details Textual)   HTML     45K 
38: R30         Valent Technologies, LLC (Details)                  HTML     49K 
39: R31         Derivative Liability (Details)                      HTML     37K 
40: R32         Derivative Liability (Details 1)                    HTML     41K 
41: R33         Derivative Liability (Details Textual)              HTML     71K 
42: R34         Stockholders' Equity (Details)                      HTML    100K 
43: R35         Stockholders' Equity (Details 1)                    HTML     30K 
44: R36         Stockholders' Equity (Details 2)                    HTML     37K 
45: R37         Stockholders' Equity (Details 3)                    HTML     40K 
46: R38         Stockholders' Equity (Details 4)                    HTML    118K 
47: R39         Stockholders' Equity (Details 5)                    HTML     38K 
48: R40         Stockholders' Equity (Details 6)                    HTML     30K 
49: R41         Stockholders' Equity (Details 7)                    HTML     51K 
50: R42         Stockholders' Equity (Details 8)                    HTML     35K 
51: R43         Stockholders' Equity (Details 9)                    HTML     58K 
52: R44         Stockholders' Equity (Details 10)                   HTML     90K 
53: R45         Stockholders' Equity (Details 11)                   HTML     33K 
54: R46         Financial Instruments (Details)                     HTML     28K 
55: R47         Related Party Transactions (Details)                HTML     23K 
56: R48         Current and Deferred Income Taxes (Details)         HTML     47K 
57: R49         Current and Deferred Income Taxes (Details 1)       HTML     44K 
58: R50         Current and Deferred Income Taxes (Details          HTML     46K 
                Textual)                                                         
59: R51         Commitments and Contingencies (Details)             HTML     27K 
60: R52         Stockholders' Equity (Details Textual)              HTML     91K 
61: R53         Stockholders' Equity (Details Textual 1)            HTML     66K 
62: R54         Stockholders' Equity (Details Textual 2)            HTML     52K 
63: R55         Stockholders' Equity (Details Textual 3)            HTML     46K 
64: R56         Supplementary Statement of Cash Flows Information   HTML     43K 
                (Details)                                                        
65: R57         Financial Risk Management (Details)                 HTML     27K 
66: R58         Financial Risk Management (Details 1)               HTML     28K 
67: R59         Financial Risk Management (Details Textual)         HTML     48K 
68: R60         Subsequent Events (Details)                         HTML     51K 
70: XML         IDEA XML File -- Filing Summary                      XML    133K 
69: EXCEL       IDEA Workbook of Financial Reports                  XLSX    101K 
 3: EX-101.INS  XBRL Instance -- dmpi-20190331                       XML   2.20M 
 5: EX-101.CAL  XBRL Calculations -- dmpi-20190331_cal               XML    142K 
 6: EX-101.DEF  XBRL Definitions -- dmpi-20190331_def                XML    703K 
 7: EX-101.LAB  XBRL Labels -- dmpi-20190331_lab                     XML   1.14M 
 8: EX-101.PRE  XBRL Presentations -- dmpi-20190331_pre              XML    897K 
 4: EX-101.SCH  XBRL Schema -- dmpi-20190331                         XSD    211K 
71: ZIP         XBRL Zipped Folder -- 0001213900-19-012524-xbrl      Zip    171K

‘EX-101.CAL’   —   XBRL Calculations — dmpi-20190331_cal

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" standalone="no" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.0a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
<!-- Field: Doc-Info; Name: Source; Value: dmpi%2D20190331.xfr; Date: 2019%2D06%2D25T08:40:43Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<link:roleRef roleURI="http://delmarpharma.com/role/DocumentAndEntityInformation" xlink:href="dmpi-20190331.xsd#DocumentAndEntityInformation" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CondensedInterimBalanceSheets" xlink:href="dmpi-20190331.xsd#CondensedInterimBalanceSheets" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CondensedInterimBalanceSheetsParenthetical" xlink:href="dmpi-20190331.xsd#CondensedInterimBalanceSheetsParenthetical" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CondensedInterimStatementsOfLossAndComprehensiveLoss" xlink:href="dmpi-20190331.xsd#CondensedInterimStatementsOfLossAndComprehensiveLoss" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="dmpi-20190331.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CondensedInterimStatementsOfCashFlows" xlink:href="dmpi-20190331.xsd#CondensedInterimStatementsOfCashFlows" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/GoingConcernNatureOfOperationsAndCorporateHistory" xlink:href="dmpi-20190331.xsd#GoingConcernNatureOfOperationsAndCorporateHistory" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SignificantAccountingPolicies" xlink:href="dmpi-20190331.xsd#SignificantAccountingPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/ValentTechnologiesLlc" xlink:href="dmpi-20190331.xsd#ValentTechnologiesLlc" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/DerivativeLiability" xlink:href="dmpi-20190331.xsd#DerivativeLiability" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquity" xlink:href="dmpi-20190331.xsd#StockholdersEquity" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialInstruments" xlink:href="dmpi-20190331.xsd#FinancialInstruments" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/RelatedPartyTransactions" xlink:href="dmpi-20190331.xsd#RelatedPartyTransactions" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxes" xlink:href="dmpi-20190331.xsd#CurrentAndDeferredIncomeTaxes" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CommitmentsAndContingencies" xlink:href="dmpi-20190331.xsd#CommitmentsAndContingencies" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SupplementaryStatementOfCashFlowsInformation" xlink:href="dmpi-20190331.xsd#SupplementaryStatementOfCashFlowsInformation" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialRiskManagement" xlink:href="dmpi-20190331.xsd#FinancialRiskManagement" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SubsequentEvents" xlink:href="dmpi-20190331.xsd#SubsequentEvents" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="dmpi-20190331.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SignificantAccountingPoliciesTables" xlink:href="dmpi-20190331.xsd#SignificantAccountingPoliciesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/DerivativeliabilityTables" xlink:href="dmpi-20190331.xsd#DerivativeliabilityTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityTables" xlink:href="dmpi-20190331.xsd#StockholdersEquityTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialInstrumentsTables" xlink:href="dmpi-20190331.xsd#FinancialInstrumentsTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesTables" xlink:href="dmpi-20190331.xsd#CurrentAndDeferredIncomeTaxesTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SupplementaryStatementOfCashFlowsInformationTables" xlink:href="dmpi-20190331.xsd#SupplementaryStatementOfCashFlowsInformationTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialRiskManagementTables" xlink:href="dmpi-20190331.xsd#FinancialRiskManagementTables" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/GoingConcernNatureOfOperationsAndCorporateHistoryDetails" xlink:href="dmpi-20190331.xsd#GoingConcernNatureOfOperationsAndCorporateHistoryDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SignificantAccountingPoliciesDetails" xlink:href="dmpi-20190331.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:href="dmpi-20190331.xsd#SignificantAccountingPoliciesDetailsTextual" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/ValentTechnologiesLlcDetails" xlink:href="dmpi-20190331.xsd#ValentTechnologiesLlcDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/DerivativeLiabilityDetails" xlink:href="dmpi-20190331.xsd#DerivativeLiabilityDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/DerivativeLiabilityDetails1" xlink:href="dmpi-20190331.xsd#DerivativeLiabilityDetails1" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/DerivativeLiabilityDetailsTextual" xlink:href="dmpi-20190331.xsd#DerivativeLiabilityDetailsTextual" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails1" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails1" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails2" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails2" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails3" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails3" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails4" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails4" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails5" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails5" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails6" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails6" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails7" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails7" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails8" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails8" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails9" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails9" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails10" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails10" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetails11" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetails11" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialInstrumentsDetails" xlink:href="dmpi-20190331.xsd#FinancialInstrumentsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/RelatedPartyTransactionsDetails" xlink:href="dmpi-20190331.xsd#RelatedPartyTransactionsDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesDetails" xlink:href="dmpi-20190331.xsd#CurrentAndDeferredIncomeTaxesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesDetails1" xlink:href="dmpi-20190331.xsd#CurrentAndDeferredIncomeTaxesDetails1" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesDetailsTextual" xlink:href="dmpi-20190331.xsd#CurrentAndDeferredIncomeTaxesDetailsTextual" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/CommitmentsAndContingenciesDetails" xlink:href="dmpi-20190331.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetailsTextual" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetailsTextual" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetailsTextual1" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetailsTextual1" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetailsTextual2" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetailsTextual2" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/StockholdersEquityDetailsTextual3" xlink:href="dmpi-20190331.xsd#StockholdersEquityDetailsTextual3" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SupplementaryStatementOfCashFlowsInformationDetails" xlink:href="dmpi-20190331.xsd#SupplementaryStatementOfCashFlowsInformationDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialRiskManagementDetails" xlink:href="dmpi-20190331.xsd#FinancialRiskManagementDetails" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialRiskManagementDetails1" xlink:href="dmpi-20190331.xsd#FinancialRiskManagementDetails1" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/FinancialRiskManagementDetailsTextual" xlink:href="dmpi-20190331.xsd#FinancialRiskManagementDetailsTextual" xlink:type="simple"/>
<link:roleRef roleURI="http://delmarpharma.com/role/SubsequentEventsDetails" xlink:href="dmpi-20190331.xsd#SubsequentEventsDetails" xlink:type="simple"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CondensedInterimBalanceSheets" xlink:title="00000002 - Statement - Consolidated Condensed Interim Balance Sheets">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_TaxesAndOtherReceivablesCurrent" xlink:label="loc_dmpiTaxesAndOtherReceivablesCurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_dmpiTaxesAndOtherReceivablesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCostsCurrentAndNoncurrent" xlink:label="loc_us-gaapDeferredCostsCurrentAndNoncurrent"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredCostsCurrentAndNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaapDueToRelatedPartiesCurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDueToRelatedPartiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesNoncurrent"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDerivativeLiabilitiesNoncurrent" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_VotingShare" xlink:label="loc_dmpiVotingShare"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_dmpiVotingShare" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CondensedInterimBalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Condensed Interim Balance Sheets (Parenthetical)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CondensedInterimStatementsOfLossAndComprehensiveLoss" xlink:title="00000004 - Statement - Consolidated Condensed Interim Statements of Loss and Comprehensive Loss">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CondensedInterimStatementsOfCashFlows" xlink:title="00000006 - Statement - Consolidated Condensed Interim Statements of Cash Flows">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_IssuanceOfStockForServices" xlink:label="loc_dmpiIssuanceOfStockForServices"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_dmpiIssuanceOfStockForServices" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_IncreaseDecreaseInTaxesAndOtherReceivables" xlink:label="loc_dmpiIncreaseDecreaseInTaxesAndOtherReceivables"/>
<link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_dmpiIncreaseDecreaseInTaxesAndOtherReceivables" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense"/>
<link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="loc_us-gaapIncreaseDecreaseInDueToRelatedParties"/>
<link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDueToRelatedParties" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_ProceedsFromIssuanceOfSharesAndWarrants" xlink:label="loc_dmpiProceedsFromIssuanceOfSharesAndWarrants"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_dmpiProceedsFromIssuanceOfSharesAndWarrants" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/GoingConcernNatureOfOperationsAndCorporateHistory" xlink:title="00000007 - Disclosure - Going Concern, Nature of Operations, and Corporate History"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Significant Accounting Policies"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/ValentTechnologiesLlc" xlink:title="00000009 - Disclosure - Valent Technologies, LLC"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/DerivativeLiability" xlink:title="00000010 - Disclosure - Derivative Liability"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquity" xlink:title="00000011 - Disclosure - Stockholders' Equity"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialInstruments" xlink:title="00000012 - Disclosure - Financial Instruments"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/RelatedPartyTransactions" xlink:title="00000013 - Disclosure - Related Party Transactions"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxes" xlink:title="00000014 - Disclosure - Current and Deferred Income Taxes"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CommitmentsAndContingencies" xlink:title="00000015 - Disclosure - Commitments and Contingencies"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SupplementaryStatementOfCashFlowsInformation" xlink:title="00000016 - Disclosure - Supplementary Statement of Cash Flows Information"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialRiskManagement" xlink:title="00000017 - Disclosure - Financial Risk Management"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - Subsequent Events"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000019 - Disclosure - Significant Accounting Policies (Policies)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000020 - Disclosure - Significant Accounting Policies (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/DerivativeliabilityTables" xlink:title="00000021 - Disclosure - Derivative Liability (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityTables" xlink:title="00000022 - Disclosure - Stockholders' Equity (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialInstrumentsTables" xlink:title="00000023 - Disclosure - Financial Instruments (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesTables" xlink:title="00000024 - Disclosure - Current and Deferred Income Taxes (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SupplementaryStatementOfCashFlowsInformationTables" xlink:title="00000025 - Disclosure - Supplementary Statement of Cash Flows Information (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialRiskManagementTables" xlink:title="00000026 - Disclosure - Financial Risk Management (Tables)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/GoingConcernNatureOfOperationsAndCorporateHistoryDetails" xlink:title="00000027 - Disclosure - Going Concern, Nature of Operations, and Corporate History (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SignificantAccountingPoliciesDetails" xlink:title="00000028 - Disclosure - Significant Accounting Policies (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SignificantAccountingPoliciesDetailsTextual" xlink:title="00000029 - Disclosure - Significant Accounting Policies (Details Textual)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/ValentTechnologiesLlcDetails" xlink:title="00000030 - Disclosure - Valent Technologies, LLC (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/DerivativeLiabilityDetails" xlink:title="00000031 - Disclosure - Derivative Liability (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/DerivativeLiabilityDetails1" xlink:title="00000032 - Disclosure - Derivative Liability (Details 1)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/DerivativeLiabilityDetailsTextual" xlink:title="00000033 - Disclosure - Derivative Liability (Details Textual)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails" xlink:title="00000034 - Disclosure - Stockholders' Equity (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails1" xlink:title="00000035 - Disclosure - Stockholders' Equity (Details 1)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails2" xlink:title="00000036 - Disclosure - Stockholders' Equity (Details 2)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails3" xlink:title="00000037 - Disclosure - Stockholders' Equity (Details 3)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails4" xlink:title="00000038 - Disclosure - Stockholders' Equity (Details 4)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails5" xlink:title="00000039 - Disclosure - Stockholders' Equity (Details 5)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails6" xlink:title="00000040 - Disclosure - Stockholders' Equity (Details 6)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails7" xlink:title="00000041 - Disclosure - Stockholders' Equity (Details 7)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails8" xlink:title="00000042 - Disclosure - Stockholders' Equity (Details 8)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails9" xlink:title="00000043 - Disclosure - Stockholders' Equity (Details 9)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails10" xlink:title="00000044 - Disclosure - Stockholders' Equity (Details 10)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetails11" xlink:title="00000045 - Disclosure - Stockholders' Equity (Details 11)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialInstrumentsDetails" xlink:title="00000046 - Disclosure - Financial Instruments (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/RelatedPartyTransactionsDetails" xlink:title="00000047 - Disclosure - Related Party Transactions (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesDetails" xlink:title="00000048 - Disclosure - Current and Deferred Income Taxes (Details)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_DeferredTaxAssetsFinancingCost" xlink:label="loc_dmpiDeferredTaxAssetsFinancingCost"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_dmpiDeferredTaxAssetsFinancingCost" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_DeferredTaxLiabilitiesScientificResearchAndDevelopment" xlink:label="loc_dmpiDeferredTaxLiabilitiesScientificResearchAndDevelopment"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_dmpiDeferredTaxLiabilitiesScientificResearchAndDevelopment" xlink:type="arc" weight="-1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesDetails1" xlink:title="00000049 - Disclosure - Current and Deferred Income Taxes (Details 1)">
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
<link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="dmpi-20190331.xsd#dmpi_IncomeTaxReconciliationPermanentDifferences" xlink:label="loc_dmpiIncomeTaxReconciliationPermanentDifferences"/>
<link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_dmpiIncomeTaxReconciliationPermanentDifferences" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
<link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate"/>
<link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
<link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaapIncomeTaxReconciliationOtherAdjustments"/>
<link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationOtherAdjustments" xlink:type="arc" weight="1"/>
<link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeTaxExpenseBenefit" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1"/>
</link:calculationLink>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CurrentAndDeferredIncomeTaxesDetailsTextual" xlink:title="00000050 - Disclosure - Current and Deferred Income Taxes (Details Textual)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000051 - Disclosure - Commitments and Contingencies (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetailsTextual" xlink:title="00000052 - Disclosure - Stockholders' Equity (Details Textual)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetailsTextual1" xlink:title="00000053 - Disclosure - Stockholders' Equity (Details Textual 1)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetailsTextual2" xlink:title="00000054 - Disclosure - Stockholders' Equity (Details Textual 2)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/StockholdersEquityDetailsTextual3" xlink:title="00000055 - Disclosure - Stockholders' Equity (Details Textual 3)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SupplementaryStatementOfCashFlowsInformationDetails" xlink:title="00000056 - Disclosure - Supplementary Statement of Cash Flows Information (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialRiskManagementDetails" xlink:title="00000057 - Disclosure - Financial Risk Management (Details)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialRiskManagementDetails1" xlink:title="00000058 - Disclosure - Financial Risk Management (Details 1)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/FinancialRiskManagementDetailsTextual" xlink:title="00000059 - Disclosure - Financial Risk Management (Details Textual)"/>
<link:calculationLink xlink:type="extended" xlink:role="http://delmarpharma.com/role/SubsequentEventsDetails" xlink:title="00000060 - Disclosure - Subsequent Events (Details)"/>
</link:linkbase>

↑Top
Filing Submission 0001213900-19-012524   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., Apr. 24, 9:09:18.1pm ET